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PERSPECTIVE

Targeting the transferrin receptor
to develop erythropoietin for
Alzheimer’s disease
Alzheimer’s disease (AD) is the sixth leading cause of death in the
United States with approximately 5.8 million Americans currently
living with AD. Due to the lack of a disease modifying treatment
for AD and the aging baby boomer generation, this number is projected to grow to 13.8 million by 2050 (Gaugler et al., 2019). Amyloid-beta (Aβ) plaque accumulation, one of the major pathological
hallmarks of AD, can begin > 20 years before clinical symptoms of
AD. By the time AD is clinically diagnosed, neuronal loss and neuropathological lesions (Aβ plaques and tau tangles) have already
occurred in many brain regions (Gaugler et al., 2019). AD dementia correlates highly with neuronal loss, and therefore, reduction
of neuropathological lesions in the AD brain at the time of clinical
diagnosis alone cannot reverse AD dementia. We propose that a
therapy that combines a reduction of neuropathological lesions of
AD along with neuronal repair and neurogenesis may be required
to treat AD dementia.
Erythropoietin (EPO), a class I cytokine and growth factor, is the
primary regulator of erythropoiesis and is widely used for the treatment of anemia and diseases associated with low plasma EPO (Rey
et al., 2019; Sun et al., 2019a). Besides its role in hematopoiesis, the
presence of EPO and its receptor in non-erythroid tissues, including
the brain, suggested a role apart from its hematopoietic effects (Rey et
al., 2019; Sun et al., 2019a). Today, numerous studies show the protective effects of EPO in various neurodegenerative conditions including
AD (Rey et al., 2019; Sun et al., 2019a). In a recent clinical study, EPO
significantly improved neuropsychological test scoring in chronic
kidney disease patients with cognitive deficits (Rey et al., 2019). The
mechanisms underlying neuroprotective effects of EPO in AD are
pleiotropic (Sun et al., 2019a), as discussed below. In experimental
AD, Lee et al. (2012) showed that EPO (5000 IU/kg per day, intraperitoneally (i.p.) for 5 days; equivalent to ~350 µg/kg per week) reduced
Aβ plaque by modulating the blood-brain barrier (BBB) influx transporter for Aβ, increased synaptophysin expression and angiogenesis
in the brain, and improved contextual memory in AD transgenic
mice. Similarly, Li et al. (2015) observed that EPO (1000 IU/kg per
day, i.p. for 2 weeks; equivalent to ~70 µg/kg per week) ameliorated
Aβ42-induced mitochondrial dysfunction, neuronal apoptosis, tau
hyperphosphorylation through the regulation of glycogen synthase
kinase-3β at multiple AD-related sites, and overall memory impairment in mice. Maurice et al. (2013) administered EPO for 4 days
(125–500 µg/kg per week, i.p.) and found a reduction in Aβ25–35induced: lipid peroxidation, Bax level, tumor necrosis factor α and
interleukin-1β, hippocampal synaptic loss and learning deficits in a
non-transgenic mouse model of AD. The work by Armand-Ugon et
al. (2015) showed that EPO (2500 IU/kg, 3 days a week for 4 weeks,
i.p.; equivalent to ~75 µg/kg per week) improved memory and reduced Aβ load in AD transgenic mice. Similar therapeutic effects of
EPO have also been demonstrated in rat AD models wherein EPO
reduced memory deficits by attenuating neuronal loss, neuroinflammation and cholinergic deficits and enhanced hippocampal
neuronal proliferation (Rey et al., 2019). Overall, the protective
effects of EPO include enhanced neurogenesis and angiogenesis,
reduced neuroinflammation, oxidative stress and mitochondrial
dysfunction, and modulation of AD-hallmark pathology (Aβ and
tau phosphorylation; Sun et al., 2019a). The typical dose of EPO
used to treat anemia is between 100–400 IU/kg per dose, which is,
many-fold lower than the dose of EPO used in the aforementioned
AD experimental studies. Large EPO doses were used in experimental AD because the large molecular weight (30.4 kDa) and polarity of EPO limit its entry into the brain across the BBB (Boado et
al., 2010). This is the first obstacle to the development of EPO for a
central nervous system disease including AD.

The second obstacle to the development of this neurotrophin for
AD is the unwanted hematopoietic adverse effects associated with
high EPO doses. This is particularly relevant while trying to develop EPO for AD due to chronicity of AD treatment and the potential
for continuous EPO receptor stimulation. There have been limited
studies reporting the hematopoietic effects of chronic EPO dosing
in experimental AD, and a recent study showed marked elevation
in hematocrit and reduction in reticulocytes with chronic EPO dosing in AD transgenic mice (Armand-Ugon et al., 2015). Alternate
non-hematopoietic variants of EPO that retain neuroprotective effects have been developed and studied (Sun et al., 2019a), however
we have taken a different approach to offset the two aforementioned
obstacles to develop EPO for AD, which will be discussed below.
A BBB-penetrable EPO has been engineered by fusing human
EPO to a chimeric monoclonal antibody against the mouse transferrin receptor (TfRMAb), and the fusion protein is designated
as TfRMAb-EPO (Zhou et al., 2010). Human EPO was fused to
the mouse TfRMAb since human EPO (reference: P01588) shares
high (78.8%) amino acid identity with the mouse EPO (reference:
P07321), binds mouse EPO receptor with high affinity and is what
will be further developed for treatment in humans. Engineering a
TfRMAb-EPO fusion protein offers dual advantages both of which
are TfR mediated: 1) the TfRMAb domain of the fusion protein acts
as a molecular Trojan horse to drive the EPO into the brain by binding to the BBB TfR and subsequent receptor mediated transcytosis,
and 2) the TfRMAb domain also binds to the peripheral TfR to aid
in systemic clearance of the TfRMAb-EPO fusion protein. The latter
accelerates the peripheral clearance, reduces the systemic plasma exposure, and is expected to alleviate the hematopoietic adverse effects
of EPO. The brain and plasma pharmacokinetics of TfRMAb-EPO
show high brain uptake (2% injected dose/g brain in the mouse following intravenous dosing) and a 10-fold higher systemic clearance
compared with EPO alone (Zhou et al., 2010).
Based on the above, in our recent work we investigated the effect
of the BBB-penetrating TfRMAb-EPO fusion protein, in comparison with EPO, in a transgenic mouse model of AD. The overall
aim was to determine if TfRMAb-EPO offers better therapeutic
and hematologic indices compared with EPO alone, as would be
expected based on the TfR-mediated BBB uptake and peripheral
clearance of TfRMAb-EPO (Sun et al., 2019b). We treated male
APP/PS1 transgenic mice (strain B6C3-Tg APPswe, PSEN1dE9,
85Dbo/Mmjax; 9.5 months of age at the start of the study), 2 days a
week with either saline, TfRMAb-EPO (3 mg/kg per dose) or EPO
(0.6 mg/kg per dose since the TfRMAb-EPO fusion protein is 20%
EPO based on amino acid content) subcutaneously for 6 weeks (Sun
et al., 2019b). Both TfRMAb-EPO and EPO significantly reduced
brain Aβ load. It has been shown that EPO can reduce the expression of receptor for advanced glycation end products which is
involved in the influx of Aβ into the brain, and both TfRMAb-EPO
and EPO can modulate the expression of receptor for advanced
glycation end products given its luminal location at the BBB. Interestingly, only the BBB-penetrating TfRMAb-EPO reduced brain
Aβ1–42 which is the more pathologic and aggregation prone isoform
of Aβ. BBB-penetrating TfRMAb-EPO also increased brain synaptophysin, a marker of synaptic function, in treated mice. EPO alone
did not alter synaptophysin levels in the brain. Memory deficits
in the mice correlated with synaptic function in our study, and
mice treated with TfRMAb-EPO did not show impaired memory,
however, mice treated with the EPO alone had significant memory
impairment (Sun et al., 2019a).
With respect to the hematopoietic effects of chronic EPO dosing,
we observed marked differences in the hematologic indices of the
mice treated with the BBB-penetrating TfRMAb-EPO and those
treated with EPO alone. AD transgenic mice treated with EPO
alone had elevated red blood cell indices (hematocrit, hemoglobin
and red blood cell count) following 4-week treatment. This increase
in the red blood cell indices is expected given the erythropoietic effects of EPO. However, TfRMAb-EPO treated mice showed
no alteration in hematocrit, hemoglobin or red blood cell count
throughout the study, and this can be explained by the lower plas2251
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Figure 1 Transferrin receptor (TfR) mediated brain uptake and
peripheral clearance of erythropoietin (EPO) fused to a monoclonal
antibody against the TfR (TfRMAb).
TfRMAb-EPO binds to blood-brain barrier (BBB) TfR enabling BBB
penetration and to peripheral TfR resulting in low plasma exposure and
a favorable hematologic profile. EPO on the other hand does not cross
the BBB in the absence of BBB disruption. Another suggested route of
EPO entry into the brain is via the BBB EPO receptors (EPOR). This
route of EPO entry into the brain is currently debated. Low EPO BBB
penetration necessitates high EPO doses for central nervous system
diseases increasing the potential for hematologic adverse effects, as seen
in our recent study (Sun et al., 2019b). The figure was created using
BioRender.com.

Taken together, the results from our recent work (Sun et al.,
2019b; Figure 1) show that while both the BBB-penetrating TfRMAb-EPO and EPO (non-BBB-penetrating) reduce total Aβ load
in the brains of AD transgenic mice, only the BBB-penetrating
TfRMAb-EPO reduced brain Aβ1–42 and increased synaptophysin.
Further, EPO significantly altered multiple hematologic indices
following chronic treatment, effects that were not seen with TfRMAb-EPO. These favorable therapeutic and hematologic effects of
TfRMAb-EPO can be attributed to the TfR-mediated BBB penetration and TfR-mediated peripheral clearance that drive the EPO into
2252
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